ProQR concludes QR-010 dosing in Phase Ib trial to treat cystic fibrosis

The Netherlands-based ProQR Therapeutics has concluded dosing patients in a Phase Ib clinical trial of QR-010 for the treatment of patients with cystic fibrosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news